Maze Therapeutics (MAZE) 44th Annual J.P. Morgan Healthcare Conference summary

Strategic vision and pipeline progress

• Focus on precision medicines for kidney and metabolic diseases using human genetics, with a strong pipeline and near-term catalysts expected in 2026 and beyond.

• Multiple clinical programs underway, including MZE829 for APOL1 kidney disease and MZE782 for PKU and chronic kidney disease.

• Operating capital secured into 2028, supporting all planned milestones and studies.

• Differentiated platform and team enable execution of milestones and expansion into additional programs.

• Commitment to updating stakeholders on progress, with key data readouts expected soon.

MZE829 for APOL1 kidney disease

• Addresses a significant unmet need with no approved therapies for APOL1-mediated kidney disease, affecting at least 250,000 individuals in the U.S.

• Phase II HORIZON study is ongoing, targeting a clinically meaningful ≥30% reduction in UACR; top-line proof-of-concept data expected by end of Q1 2026.

• Study includes both diabetic and non-diabetic patients, with a third cohort for highly proteinuric FSGS patients.

• Positive phase I data supported advancement, showing a favorable safety profile and dose selection for broad AMKD.

• If successful, planning for phase IIB/III and potential registration strategies will begin.

MZE782 for PKU and chronic kidney disease

• MZE782 aims to address PKU by enabling a more normal diet and reducing phenylalanine accumulation, with phase II study initiation planned for mid-2026.

• Demonstrated >40-fold increase in urinary phenylalanine excretion in phase I, exceeding benchmarks and generating strong enthusiasm.

• Also advancing in chronic kidney disease, with phase II start targeted for the second half of 2026.

• Preclinical and phase I data show potential to complement or replace SGLT2 inhibitors, with additive effects and a similar eGFR dip indicating long-term renal protection.

• Strategic sequencing prioritizes PKU for a clear registrational path, with pricing and product configuration considerations for broader indications.